Skip to content

Observational Study With Mode of Action-Analysis of Cystorenal Cranberry Extract in Patients With Recurrent Urinary Tract Infections

Observational Study With Mode of Action-Analysis of Cystorenal Cranberry Extract in Patients With Recurrent Urinary Tract Infections

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03019874
Enrollment
23
Registered
2017-01-13
Start date
2017-01-31
Completion date
2019-02-28
Last updated
2021-02-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Urinary Tract Infections

Brief summary

The main focus of this observational study is to analyze the possible effects of cranberry dietary supplements on the intestinal microbiota in women with recurrent uncomplicated urinary tract infections. In a secondary analysis the possible influence of the microbiota changes on the recurrence frequency in the follow-up should be analyzed.

Interventions

DIETARY_SUPPLEMENTCranberry Extract

3 x Cystorenal Cranberry plus daily for 6 months (contains 300 mg Cranberry-Extract, 100 mg Pumpkin seeds-Extract, 20 mg Vitamin C und 0,47 mg Riboflavin)

Sponsors

Charite University, Berlin, Germany
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

• chronic recurrent urinary tract infections (≥3 infections per year or 2 infections in the last 6 months)

Exclusion criteria

* renal insufficiency (GFR \<60), * anatomical or known structural causes of urinary tract infections * regular consumption of probiotics or probiotic yogurts (at least 5x / week) * intake of antibiotics in the last 4 weeks * intake of Marcumar * simultaneous participation in another study

Design outcomes

Primary

MeasureTime frame
Number of urinary tract infectionsIn the 6-month prospective observation period compared to a 6-month retrospective period

Secondary

MeasureTime frame
Quality of life (SF-36)Baseline, 4 weeks, 8 weeks, 6 months

Other

MeasureTime frame
Stool analysis: Intestinal microbiome by sequencing 16S rRNABaseline, 4 weeks, 8 weeks, 6 months

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026